Schering-Plough news from FiercePharma
NewsU.S. Attys probe Schering over Vytorin
The ranks of investigators probing Schering-Plough and its Vytorin drug are broadening. In a recent SEC filing, Schering disclosed that U.S. Attorneys have been asking for info and documents related Read more...
FDA nixes Merck, Schering allergy combo
In another blow to the Merck/Schering-Plough joint venture, the FDA rejected a proposed allergy and asthma treatment that would have Read more...
GSK, Schering-Plough profits drop
When big drugs tank, they take their makers down with them. Witness first-quarter reports from GlaxoSmithKline and Schering-Plough. GSK is suffering on a Read more...
Vytorin news buried in Merck report
Read deep into Merck's first-quarter earnings report and you'll find some Vytorin secrets spilled. First off, the company expects to lose some $700 million in revenues off the blockbuster Read more...
Did Vytorin data really need cleanup?
What would bring one Vytorin-study consultant to say, "I'm an honest guy, and my first obligation is to tell the truth. Even if it means I'll probably never get to do a scientific investigation Read more...
Vytorin records created after the fact
Misleading minutes, swearing execs--just another day at the office for Vytorin's critics. Merck and Schering-Plough face new questions about their controversial Enhance trial as a Congressional Read more...
Arms twisted, pharma promises disclosure
Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. You know, the money Read more...
A turbulent week for Fred Hassan
Wonder what it was like to be Fred Hassan (photo) last week, when his top products were getting hammered first Read more...
Schering-Plough laying off 5,500
Schering-Plough has proven quick on the layoff trigger. The company announced a plan to cut costs by $1.5 billion by 2012 in the wake of the latest round of Vytorin controversy. Roughly 5,500 Read more...
UnitedHealth stands by Vytorin
We didn't have to wait long for a Vytorin decision from UnitedHealth Group. The largest U.S. insurer says Read more...
| Press ReleasesSchering-Plough Announces NDA for Sugammadex Assigned Priority Review Status by FDA Schering-Plough Announces NDA for Sugammadex Assigned Priority Review Status by U.S. FDA KENILWORTH, N.J., Jan 02, 2008 -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food Read more... PRESS RELEASE: Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA KENILWORTH, N.J., Nov. 26 -- Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) Read more... PRESS RELEASE: Schering-Plough Corporation Completes $14.43 Billion Acquisition of Organon Schering-Plough Corporation Completes $14.43 Billion Acquisition of Organon KENILWORTH, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that it has completed the Read more... PRESS RELEASE: Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis BOSTON, Nov. 7 -- Patients with active psoriatic Read more... PRESS RELEASE: Schering-Plough Reports Financial Results for Third Quarter of 2007 Schering-Plough Reports Financial Results for Third Quarter of 2007 Solid Performance Continues in Third Quarter of 2007; Company Prepares for Integration of Organon BioSciences KENILWORTH, N.J., Read more... |
Get more Schering-Plough coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight